Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TYPER trial of typology-based coaching to improve adjuvant ribociclib treatment management in early HR-positive/HER2-negative breast cancer
2024-520290-12-00Phase 4Authorised
- Sponsor
- Institut Frauengesundheit
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ribociclib in breast cancer (2 arms), sponsored by Institut Frauengesundheit. Primary endpoint: Time to permanent treatment discontinuation of ribociclib therapy. Planned start Nov 2025; status: authorised.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-520290-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520290-12-00.